Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA 3rd.
Weiss GJ, et al. Among authors: bendell jc.
Clin Cancer Res. 2011 May 1;17(9):2997-3004. doi: 10.1158/1078-0432.CCR-10-3425. Epub 2011 Mar 17.
Clin Cancer Res. 2011.
PMID: 21415214
Clinical Trial.